A Mechanistic Paradigm for Broad-Spectrum Antivirals that Target Virus-Cell Fusion

Vigant, Frederic; Lee, Jihye; Hollmann, Axel; Tanner, Lukas B.; Akyol Ataman, Zeynep; Yun, Tatyana; Shui, Guanghou; Aguilar, Hector C.; Zhang, Dong; Meriwether, David; Roman-Sosa, Gleyder; Robinson, Lindsey R.; Juelich, Terry L.; Buczkowski, Hubert; Chou, Sunwen; Castanho, Miguel A. R. B.; Wolf, Mike C.; Smith, Jennifer K.; Banyard, Ashley; Kielian, Margaret; Reddy, Srinivasa; Wenk, Markus R.; Selke, Matthias; Santos, Nuno C.; Freiberg, Alexander N.; Jung, Michael E.; Lee, Benhur

Published in

Public Library of Science, PLoS Pathogens, 4(9), p. e1003297, 2013

DOI: 10.1371/journal.ppat.1003297

Tools

Export citation

Search in Google Scholar

A Mechanistic Paradigm for Broad-Spectrum Antivirals that Target Virus-Cell Fusion

Journal article published in 2013 by Frederic Vigant, Jihye Lee, Axel Hollmann, Lukas B. Tanner, Zeynep Akyol Ataman, Tatyana Yun, Guanghou Shui, Hector C. Aguilar, Dong Zhang, David Meriwether, Gleyder Roman-Sosa, Lindsey R. Robinson, Terry L. Juelich, Hubert Buczkowski, Sunwen Chou and other authors.

This paper is made freely available by the publisher.

Full text: Download

Preprint: archiving allowed

Upload

Postprint: archiving allowed

Upload

Published version: archiving allowed

Upload

Policy details

Data provided by

Abstract

LJ001 is a lipophilic thiazolidine derivative that inhibits the entry of numerous enveloped viruses at non-cytotoxic concentrations (IC50≤0.5 µM), and was posited to exploit the physiological difference between static viral membranes and biogenic cellular membranes. We now report on the molecular mechanism that results in LJ001's specific inhibition of virus-cell fusion.

Published in

Links

Tools

A Mechanistic Paradigm for Broad-Spectrum Antivirals that Target Virus-Cell Fusion

Abstract